Abstract
6665 Background: Optimal HDC strategy in breast cancer remains to be defined. This phase III trial evaluates the role of the number of HDC cycles. Methods: From 2/97 to 6/01 we randomised 187 patients to single or to tandem HDC. Patients were eligible if they were hormone refractory and achieved complete or partial remission after 4 to 6 cycles of standard induction chemotherapy. Patients were stratified according to remission status and localisation of metastases (bone or visceral). HDC consisted of once or twice STAMP V with cyclophosphamide, carboplatinum and thiotepa (6000/800/500 mg/m2) the tandem given at an interval of 35 days.Pts. (single/tandem): mean age 45.7/45.1 yrs, prior adjuvant chemotherapy 41%/40%, ER +: 49%/43%, mean recurrence-free interval: 45.4/37.9 months. 11% of patients had isolated bone metastases. Induction chemotherapy consisted in 51% /48 % of a combination of anthracylines and taxanes. 14 % of patients in the single and 43 % of patients in the tandem-HDC arm did not receive the planned treatment. Results: Toxicity data were reported earlier (Proc ASCO 17:141a,1997). Treatment related mortality was 3,6 %. After exclusion of drop outs CR rates are 46% in the tandem and 33% in the single HDC arm. With a median follow-up of 24 months the intent to treat analysis shows progression-free survival rates of 36%/43% after two years and 6%/12% after three years (p=0.055) in favour of the tandem. Overall survival rates were 55% and 48% after two and 18% and 21% at five years with a median overall survival of 29.4 versus 23.5 months (p =0.46) Conclusions: Tandem STAMP V induces higher complete remission rates and non significantly higher progression-free survival rates. Overall survival is not affected. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis Angem
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.